WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer

The World Health Organization’s cancer research arm has concluded that the widely used artificial sweetener aspartame is “possibly carcinogenic to humans.” (Reuters)

A large matched case-control study identified seven risk factors associated with sporadic colorectal cancer in younger men. (Cancer Prevention Research)

Polycystic ovary syndrome doubles a woman’s likelihood of developing postmenopausal ovarian cancer. (International Journal of Cancer)

A five-drug cocktail and stem-cell transplant combination improved 30-month survival in “ultra-high-risk” multiple myeloma by 50% as compared with a standard-of-care regimen. (Institute for Cancer Research)

Agios Pharmaceuticals announced that both doses of mitapivat (Pyrukynd) met the primary endpoint of hemoglobin response in sickle cell disease in a phase II trial.

Nkarta announced that its novel off-the-shelf allogeneic CAR NK-cell therapy, NKX101, with cytarabine lymphodepletion achieved complete responses in four of six patients with relapsed/refractory acute myeloid leukemia in a phase I dose-finding study.

Genmab and AbbVie announced that the T-cell engaging bispecific antibody epcoritamab (Epkinly) produced an overall response rate of 82% in a phase I/II of patients with relapsed/refractory follicular lymphoma.

In an era of million-dollar drugs, a shortage of two chemotherapy agents that cost $15 to $25 could mean the difference between life and death for some cancer patients. (New York Times)

The shutdown of an Indian pharmaceutical plant because of quality-control issues eliminated half the U.S. supply of the cancer drug cisplatin, currently in critical shortage. (Washington Post)

In laboratory studies, a single dose of an experimental monoclonal antibody targeting Notch signaling before stem-cell transplant prevented graft-versus-host disease. (Penn Medicine, Science Translational Medicine)

Patients who have unmet supportive-care needs have worse outcomes in cancer. (JAMA Network Open)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Please enable JavaScript to view the

comments powered by Disqus.